MDMarco Distefano

Marco Distefano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marco Distefano has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quantifying Esophageal Hydrogen Ion Exposure using a novel pH-impedance metric improves prediction of PPI response compared with conventional acid exposure time in GERD

    by Mentore Ribolsi, Lorenzo Marchetti, Chiara Catamo, Laura Galdi, Marco Distefano, Michele Cicala

    Background: Acid exposure time (AET) is the reference metric quantifying esophageal acid burden, yet patients with pathological AET may fail to respond to PPI therapy. Given the logarithmic nature of pH, AET does not account for the exponential increase in hydrogen ion (H + ) concentration at lower pH values. Aim: To quantify acid burden using total integrated acidity exposure (TIAE), a dose-based metric integrating H + load over time, and to assess whether TIAE improves prediction of PPI response compared with conventional AET. Methods: Impedance-pH data were retrospectively evaluated. TIAE was calculated by integrating H + concentration (10 -pH ) at 1-second resolution across all acid reflux episodes. Diagnostic performance for PPI response was assessed using ROC analysis, multivariable logistic regression and decision curve analysis (DCA). Results: Among 174 patients (97 PPI responders, 77 non-responders), responders exhibited higher TIAE than non-responders and controls (p+ load provides a physiologically grounded assessment of esophageal acid burden and improves prediction of PPI response.


  • Open Access

    Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency

    by Romain Lévy, Florian Gothe, Mana Momenilandi, Thomas Magg, Marie Materna, Philipp Peters, Johannes Raedler, Quentin Philippot, Anita Lena Rack-Hoch, David Langlais, et al.

    Patients with inherited CARMIL2 or CD28 deficiency have defective T cell CD28 signaling, but their immunological and clinical phenotypes remain largely unknown. We show that only one of three CARMIL2 isoforms is produced and functional across leukocyte subsets. Tested mutant CARMIL2 alleles from 89 patients and 52 families impair canonical NF-κB but not AP-1 and NFAT activation in T cells stimulated via CD28. Like CD28-deficient patients, CARMIL2-deficient patients display recalcitrant warts and low blood counts of CD4+ and CD8+ memory T cells and CD4+ TREGs. Unlike CD28-deficient patients, they have low counts of NK cells and memory B cells, and their antibody responses are weak. CARMIL2 deficiency is fully penetrant by the age of 10 yr and is characterized by numerous infections, EBV+ smooth muscle tumors, and mucocutaneous inflammation, including inflammatory bowel disease. Patients with somatic reversions of a mutant allele in CD4+ T cells have milder phenotypes. Our study suggests that CARMIL2 governs immunological pathways beyond CD28.